Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2016 - 2024)
Historic Asset Writedowns and Impairment for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Q1 2024 value amounting to $679.0 million.
- Teva Pharmaceutical Industries' Asset Writedowns and Impairment rose 25925.93% to $679.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $869.0 million, marking a year-over-year decrease of 6484.63%. This contributed to the annual value of $1.0 billion for FY2025, which is 1937.25% down from last year.
- As of Q1 2024, Teva Pharmaceutical Industries' Asset Writedowns and Impairment stood at $679.0 million, which was up 25925.93% from -$632.0 million recorded in Q4 2023.
- In the past 5 years, Teva Pharmaceutical Industries' Asset Writedowns and Impairment ranged from a high of $5.2 billion in Q3 2020 and a low of -$632.0 million during Q4 2023
- Moreover, its 5-year median value for Asset Writedowns and Impairment was $227.0 million (2021), whereas its average is $625.6 million.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Asset Writedowns and Impairment skyrocketed by 243365.85% in 2020, and later plummeted by 14373.7% in 2023.
- Teva Pharmaceutical Industries' Asset Writedowns and Impairment (Quarter) stood at $232.0 million in 2020, then dropped by 21.12% to $183.0 million in 2021, then surged by 689.62% to $1.4 billion in 2022, then crashed by 143.74% to -$632.0 million in 2023, then soared by 207.44% to $679.0 million in 2024.
- Its Asset Writedowns and Impairment was $679.0 million in Q1 2024, compared to -$632.0 million in Q4 2023 and $48.0 million in Q3 2023.